Literature DB >> 10873062

Gain-of-function mutations in the tumor suppressor gene p53.

M G van Oijen1, P J Slootweg.   

Abstract

The tumor suppressor protein p53 is a multifunctional transcription factor involved in the control of cell cycle progression, DNA integrity, and cell survival. p53 is mutated in half of all tumors and has a wide spectrum of mutation types. p53 mutants show different degrees of dominance over coexpressed wild-type p53, and loss of the wild-type p53 allele has been observed frequently. Several p53 mutants can exert oncogenic functions beyond their negative domination over the wild-type p53 tumor suppressor functions. These so-called gain-of-function effects, such as enhancement of tumorigenicity and therapy resistance, were investigated in p53-null cells. The possible mechanisms by which p53 mutants exert their gain-of-function effects are reviewed. The existence of functional gains of certain p53 mutants has important ramifications for tumor prognosis and cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873062

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

1.  The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.

Authors:  Siddharth Singh; Manoj Kumar; Sanjeev Kumar; Shrinka Sen; Pawan Upadhyay; Sayan Bhattacharjee; Naveen M; Vivek Singh Tomar; Siddhartha Roy; Amit Dutt; Tapas K Kundu
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

2.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  RMut: R package for a Boolean sensitivity analysis against various types of mutations.

Authors:  Hung-Cuong Trinh; Yung-Keun Kwon
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

4.  Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China.

Authors:  Zhu Ke-Xiang; Li Yu-Min; Li Xun; Zhou Wen-Ce; Shan Yong; Liu Tao
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

5.  Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Authors:  Shengliang Zhang; Lanlan Zhou; Bo Hong; A Pieter J van den Heuvel; Varun V Prabhu; Noel A Warfel; Christina Leah B Kline; David T Dicker; Levy Kopelovich; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

6.  Limitations of the 'ambush hypothesis' at the single-gene scale: what codon biases are to blame?

Authors:  Robert L Bertrand; Mona Abdel-Hameed; John L Sorensen
Journal:  Mol Genet Genomics       Date:  2014-10-12       Impact factor: 3.291

7.  Platelet-to-lymphocyte ratio predicts long-term survival in laryngeal cancer.

Authors:  Yize Mao; Yan Fu; Yunfei Gao; Ankui Yang; Quan Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-23       Impact factor: 2.503

Review 8.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

9.  Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Authors:  I Kogan-Sakin; Y Tabach; Y Buganim; A Molchadsky; H Solomon; S Madar; I Kamer; P Stambolsky; A Shelly; N Goldfinger; S Valsesia-Wittmann; A Puisieux; A Zundelevich; E N Gal-Yam; C Avivi; I Barshack; M Brait; D Sidransky; E Domany; V Rotter
Journal:  Cell Death Differ       Date:  2010-08-06       Impact factor: 15.828

10.  A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer.

Authors:  Sun Young Yi; Woon Jung Lee
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.